A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
NCT ID: NCT06523803
Last Updated: 2025-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
32 participants
INTERVENTIONAL
2024-09-30
2025-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer
NCT05372692
Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
NCT00945191
ZW25 in Women With Endometrial Cancers
NCT04513665
An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer
NCT07096583
Study of DP303c Injection in Patients With Advanced Ovarian Cancer
NCT04828616
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ZW171
ZW171
Administered per protocol requirements
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ZW171
Administered per protocol requirements
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
* Adequate cardiac left ventricular function, as defined by left ventricular ejection fraction ≥ 50% as determined by either echocardiogram or multigated acquisition scan.
* Adequate organ function.
Exclusion Criteria
* Undergone prior allogenic tissue (e.g., hematopoietic stem cell) or solid organ transplantation within the last 5 years.
* Ongoing, clinically significant toxicity (Grade ≥ 2) associated with prior cancer therapies, with the exception of alopecia.
* Advanced/metastatic, symptomatic, visceral spread, at risk of life-threatening complications in the short-term (including participants with massive uncontrolled effusion \[pleural, pericardial\], pulmonary lymphangitis, active unresolved bowel obstruction, massive ascites \[requiring paracentesis \>2 times within 2 weeks prior to the first dose\], and over 50% liver involvement).
* Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of participants with Gilbert's Syndrome, asymptomatic gall stones, liver metastases, or stable chronic liver disease per investigator assessment).
* Active or recurrent clinically significant autoimmune disease requiring systemic high-dose corticosteroids or immunosuppressive drugs.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zymeworks BC Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pranshul Chauhan, MSc, MB, BCh, BAO
Role: STUDY_DIRECTOR
Zymeworks BC Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Southern California - Norris Comprehensive Cancer Center
Los Angeles, California, United States
University of Colorado Health Sciences Center
Aurora, Colorado, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Icahn School of Medicine at Mount Sinai (ISMMS) - The Blavatnik Family-Chelsea Medical Center
New York, New York, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
University of Washington
Seattle, Washington, United States
Universitaetsklinikum Dresden
Dresden, , Germany
Seoul National University Hospital
Seoul, , South Korea
Yonsei University Health System - Severance Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
The Catholic University of Korea, Seoul St. Marys Hospital
Seoul, , South Korea
Guys and St Thomas' NHS Foundation Trust
London, , United Kingdom
The Christie NHS Foundation Trust
Manchester, , United Kingdom
Royal Marsden Hospital
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-511119-11
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
ZWI-ZW171-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.